{
    "Trade/Device Name(s)": [
        "Wondfo Amphetamine Urine Test",
        "Wondfo Secobarbital Urine Test",
        "Wondfo Oxazepam Urine Test",
        "Amphetamine Urine Test",
        "Secobarbital Urine Test",
        "Oxazepam Urine Test"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K111560",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020771"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "DIS",
        "JXM",
        "DIX"
    ],
    "Summary Letter Date": "July 6, 2011",
    "Summary Letter Received Date": "July 8, 2011",
    "Submission Date": "May 03, 2011",
    "Regulation Number(s)": [
        "21CFR862.3100",
        "21CFR862.3150",
        "21CFR862.3170"
    ],
    "Regulation Name(s)": [
        "Amphetamine Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Secobarbital",
        "Oxazepam"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunochemistry",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Strip",
        "Cassette"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo qualitative lateral flow immunochromatographic assays for Amphetamine, Secobarbital, and Oxazepam detection in urine",
    "Indications for Use Summary": "For qualitative determination of amphetamine, secobarbital, and oxazepam in human urine at specific cut-off concentrations for prescription and over-the-counter use",
    "fda_folder": "Toxicology"
}